New hope for kidney patients: diabetes drugs tested for nephrotic syndrome

NCT ID NCT07214818

First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 21 times

Summary

This study tests whether two diabetes drugs (dapagliflozin and empagliflozin) can help adults with nephrotic syndrome, a kidney condition causing protein leakage and swelling. 75 participants will receive either one of the drugs plus standard care, or standard care alone, and be followed for 6 months. The goal is to see if these drugs reduce protein in urine, maintain remission, and prevent relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Urology & Nephrology Center, Mansoura University

    Al Mansurah, Dakahlia Governorate, 35516, Egypt

Conditions

Explore the condition pages connected to this study.